...
首页> 外文期刊>Clinical and Translational Medicine >Integrated EpCAM-independent subtraction enrichment and iFISH strategies to detect and classify disseminated and circulating tumors cells
【24h】

Integrated EpCAM-independent subtraction enrichment and iFISH strategies to detect and classify disseminated and circulating tumors cells

机译:集成的不依赖EpCAM的减法富集和iFISH策略来检测和分类已扩散和循环的肿瘤细胞

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Application of tumor cell surface adhesion molecule EpCAM-dependent antibody capture, and intracellular cytokeratins (CKs)-dependent immunostaining strategies to detect disseminated or circulating tumor cells (DTCs or CTCs), is limited by highly heterogeneous and dynamic expression or absence of EpCAM and/or CKs in CTCs and DTCs, particularly in their capturing and identifying CTCs/DTCs shed from diverse types of solid tumor, thus being biased and restricted to the only both EpCAM and CK positive cancer cells. Moreover, heterogeneity of chromosome and tumor biomarker of CTCs/DTCs cannot be co-examined by conventional CK/EpCAM-dependent techniques. Accordingly, a novel integrated cellular and molecular approach of EpCAM-independent subtraction enrichment (SE) and immunostaining-FISH (iFISH~(?)) has recently been successfully developed. SE-iFISH~(?)is able to effectively enrich, comprehensively identify and characterize both large and small size non-hematopoietic heteroploid CTCs, DTCs and circulating tumor microemboli in various biofluid specimens of either cancer patients or patient-derived-xenograft mice. Obtained tumor cells, free of anti-EpCAM perturbing and hypotonic damage, are eligible for primary tumor cell culture as well as a series of downstream analyses. Highly heterogeneous CTCs and DTCs could be classified into subtypes by in situ phenotyping protein expression of various tumor biomarkers and karyotyping of chromosome aneuploidy performed by iFISH~(?). Each CTC subtype may correlate with distinct clinical significance in terms of tumor metastasis, relapse, therapeutic drug sensitivity or resistance, respectively.
机译:高度异质和动态表达或不存在EpCAM和//限制了肿瘤细胞表面粘附分子EpCAM依赖的抗体捕获和细胞内细胞角蛋白(CKs)依赖的免疫染色策略来检测已扩散或循环的肿瘤细胞(DTC或CTC)的应用。 CTC和DTC中的CKs,特别是在捕获和鉴定来自各种类型实体瘤的CTC / DTCs中,因此受到偏见并仅限于EpCAM和CK阳性癌细胞。而且,不能通过常规的CK / EpCAM依赖性技术来共同检查CTC / DTC的染色体异质性和肿瘤生物标志物。因此,最近已经成功地开发了一种新的整合了细胞和分子的不依赖EpCAM的减法富集(SE)和免疫染色FISH(iFISH〜(?))的方法。 SE-iFISH〜(?)能够有效地富集,全面鉴定和表征癌症患者或患者来源的异种移植小鼠的各种生物流体标本中的大,小尺寸非造血异倍体CTC,DTC和循环肿瘤微栓子。所获得的肿瘤细胞无抗EpCAM干扰和低渗性损伤,可用于原代肿瘤细胞培养以及一系列下游分析。高度异质的CT​​C和DTC可以通过各种肿瘤生物标记物的原位表型蛋白表达和iFISH〜(?)进行的染色体非整倍性染色体核型分型。每种CTC亚型可能分别在肿瘤转移,复发,治疗药物敏感性或耐药性方面与独特的临床意义相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号